内容紹介
A Case of Lung Cancer Pain Relief and Safe Return Home by Strontium Chloride
Summary
Strontium chloride 89(89Sr)is used as a systemic radiopharmaceutical therapy for the palliation of pain in patients with metastatic bone cancer. A 64-year-old man had previously undergone an operation to resect his right upper lobe of lung and sixth rib. He was diagnosed with lung cancer(large cell carcinoma, pT3N0M0, stage ⅡB). Three months later, he was treated with chemoradiotherapy for local recurrence. Ten months later, he could not sit up due to severe pain of the left ilium, although he had been treated with opiate analgesics. Fourteen months later, his hospital stay was prolonged and he was treated with 89Sr. One week after injection, the pain was almost completed relieved. Two weeks after injection, morphine infusion was stopped and a reduced dose of a fentanyl patch was used. He was also able to eat meals. Three weeks after injection, he started rehabilitation. Two months after the injection of 89Sr, he could return home from the hospital. Adverse events included grade 2 leukopenia, neutropenia and thrombocytopenia. These peaked 2 months after injection.
要旨
塩化ストロンチウム(89Sr)は多発性骨転移の癌性疼痛緩和に使用する放射線性医薬品である。症例は64歳,男性。肺癌に対して右上葉切除および第6肋骨切除術を施行された。大細胞癌,pT3N0M0,stage ⅡBであった。3か月後に局所再発し放射線療法と化学療法を施行した。10か月後には骨転移による激しい左腸骨部疼痛のため麻薬鎮痛薬で治療するも起居困難となった。長期入院となり14か月後に89Srを投与。投与1週間後に疼痛はほぼ消失。2週間後にモルヒネ点滴終了とフェンタニル貼付剤を減量し食事を開始。3週間後にリハビリ開始。89Sr投与2か月後に自宅へ退院することができた。有害事象として2か月後をピークにgrade 2の白血球減少,好中球減少,血小板減少を認めた。
目次
Summary
Strontium chloride 89(89Sr)is used as a systemic radiopharmaceutical therapy for the palliation of pain in patients with metastatic bone cancer. A 64-year-old man had previously undergone an operation to resect his right upper lobe of lung and sixth rib. He was diagnosed with lung cancer(large cell carcinoma, pT3N0M0, stage ⅡB). Three months later, he was treated with chemoradiotherapy for local recurrence. Ten months later, he could not sit up due to severe pain of the left ilium, although he had been treated with opiate analgesics. Fourteen months later, his hospital stay was prolonged and he was treated with 89Sr. One week after injection, the pain was almost completed relieved. Two weeks after injection, morphine infusion was stopped and a reduced dose of a fentanyl patch was used. He was also able to eat meals. Three weeks after injection, he started rehabilitation. Two months after the injection of 89Sr, he could return home from the hospital. Adverse events included grade 2 leukopenia, neutropenia and thrombocytopenia. These peaked 2 months after injection.
要旨
塩化ストロンチウム(89Sr)は多発性骨転移の癌性疼痛緩和に使用する放射線性医薬品である。症例は64歳,男性。肺癌に対して右上葉切除および第6肋骨切除術を施行された。大細胞癌,pT3N0M0,stage ⅡBであった。3か月後に局所再発し放射線療法と化学療法を施行した。10か月後には骨転移による激しい左腸骨部疼痛のため麻薬鎮痛薬で治療するも起居困難となった。長期入院となり14か月後に89Srを投与。投与1週間後に疼痛はほぼ消失。2週間後にモルヒネ点滴終了とフェンタニル貼付剤を減量し食事を開始。3週間後にリハビリ開始。89Sr投与2か月後に自宅へ退院することができた。有害事象として2か月後をピークにgrade 2の白血球減少,好中球減少,血小板減少を認めた。